Quzhou Kaixiang Biological Tech Co., Ltd. – Trademark Portfolio

Entity Type: 99

Quzhou Kaixiang Biological Tech Co., Ltd. holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 11 (Environmental Control) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include AMRLISH. The owner is based in Zhejiang Province.

Room 202, Building 1, No. 6, Tongsheng

Zhejiang Province 324000 , CN

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

AMRLISH
AMRLISH
Registered 2021

Trademark Classifications

Quzhou Kaixiang Biological Tech Co., Ltd.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

11
Environmental Control (1 filing)

Apparatus for lighting, heating, steam generating, cooking, refrigerating, drying

Frequently Asked Questions

How many trademarks does Quzhou Kaixiang Biological Tech Co., Ltd. have?

Quzhou Kaixiang Biological Tech Co., Ltd. has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does Quzhou Kaixiang Biological Tech Co., Ltd. file in?

Quzhou Kaixiang Biological Tech Co., Ltd. files trademarks across 1 Nice Classification class. The most active classes are Class 11 (Environmental Control). Class 11 covers apparatus for lighting, heating, steam generating, cooking, refrigerating, drying.

What are Quzhou Kaixiang Biological Tech Co., Ltd.'s most well-known trademarks?

Quzhou Kaixiang Biological Tech Co., Ltd.'s registered trademark portfolio includes well-known marks such as AMRLISH. These are among 1 currently registered trademark in the portfolio.

What is Quzhou Kaixiang Biological Tech Co., Ltd.'s trademark registration success rate?

Quzhou Kaixiang Biological Tech Co., Ltd. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.